金吾财讯 | 摩根大通发布最新研究报告，将Biogen（BIIB）的股票评级从“中性”大幅上调至“增持”，并将其目标价设定为300美元，相较前一交易日收盘价具备约33%的潜在上涨空间。摩根大通分析师克里斯托弗·肖特在报告中明确指出，随着公司研发管线中多款具备吸引力的重磅药物将在2027年迎来关键进展，Biogen的长期增长前景已显著改善。分析师强调，Biogen的发展格局正迎来实质性转变，其增长驱动力将不再仅局限于阿尔茨海默病药物Leqembi的销售情况，多元化的新药储备正逐步落地。该行提到，本月初，Biogen公布了其研发中的红斑狼疮候选药物Litifilimab在中期临床试验中的持久疗效数据，显示该药物对自身免疫性疾病患者的皮肤症状改善效果显著，有效提振了市场对其免疫领域的信心。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.